News in other languages: NEOVACS

07/08	Bourse : Eutelsat souffre, la tech américaine s'offre un baroud d'honneur nocturne
07/08	Néovacs accepte un accord stratégique à plus de 25 millions de dollars
07/08	Neovacs : Néovacs a accepté une lettre d’intention engageante portant sur l’acquisition d’une partie de sa propriété intellectuelle et un accompagnement dans leur valorisation pour un montant total pouvant dépasser 25 MEUR
07/08	L'énigmatique Mister Warsh, le marché du travail et les taux
30/06	Neovacs renforce son portefeuille stratégique de propriété intellectuelle

More news

Managers and Directors: NEOVACS

Manager	Title	Age	Since
Hugo Brugière CEO	Chief Executive Officer	-	-
Alexandre Courtoux DFI	Director of Finance/CFO	-	01/10/2020
Laurent Reber CTO	Chief Tech/Sci/R&D Officer	56	-

Director	Title	Age	Since
Jean-Jacques Bertrand CHM	Chairman	87	28/05/2003
Baudouin Hallo BRD	Director/Board Member	-	01/05/2020
Hugo Brugière CHM	Chairman	-	-

More insiders

Other Biotechnology & Medical Research

Add to a list 0 selected To use this feature you must be a member Log in Sign up	Change	5-day change	1-year change	3-year change	Capi.($)
NEOVACS	+0.07%	-10.21%	-99.99%	-100.00%	114K
LONZA GROUP AG	-0.68%	+3.88%	+2.72%	+23.23%	51.61B
REVOLUTION MEDICINES, INC.	-1.07%	+2.82%	+465.96%	+570.70%	44.89B
IQVIA HOLDINGS INC.	+1.47%	+9.79%	+35.92%	+20.21%	42.77B
BEONE MEDICINES AG	+1.44%	+7.77%	+19.38%	+84.65%	42.58B
CELLTRION, INC.	-0.93%	-4.33%	+16.18%	+55.82%	31.82B
MEDPACE HOLDINGS, INC.	+1.32%	+7.30%	+33.89%	+148.53%	17.33B
ASCENDIS PHARMA A/S	-0.60%	+1.93%	-	-	16.63B
EUROFINS SCIENTIFIC SE	+0.41%	+4.49%	+9.59%	+30.65%	14.76B
CHARLES RIVER LABORATORIES INTERNATIONAL, INC.	+1.28%	+5.41%	+82.40%	+46.13%	14.09B
Average	+0.27%	+2.94%	+62.89%	+97.77%	27.65B
Weighted average by Cap.	+0.18%	+4.72%	+99.39%	+141.40%

See all sector performances

NEOVACS is a major player in the therapeutic vaccines for the treatment of autoimmune and / or inflammatory diseases. Its proprietary products are vaccine candidates developed from its own technology platform for Kinoid products used in lupus disease and allergies. This innovative approach allows the patient's immune system to regulate the damage caused by overproduction of cytokines (active immunotherapy) such as IL-4/IL-13/IgE. The company also uses the skills of its experienced team to invest in companies developing innovative products (BioTech) and medical devices (MedTech).

Employees

Sector

Biotechnology & Medical Research

More about the company

Quotes

Date	Price	Change	Volume
24/08/26	EUR 0.6124	+0.07%	10,363
21/08/26	EUR 0.6120	-10.00%	38,154
20/08/26	EUR 0.6800	-5.56%	38,259
19/08/26	EUR 0.7200	-5.26%	84,466
18/08/26	EUR 0.7600	+11.44%	141,734

Real-time Euronext Paris

More quotes

Select your edition

All financial news and data tailored to specific country editions

NORTH AMERICA

United-States

Canada

Real-time Euronext Paris 07:45:23 24/08/26 pm AEST			5-day change	1st Jan Change
0.6124 ^EUR	+0.07%		-10.21%	-99.30%

30/06	Neovacs bolsters its strategic intellectual property portfolio
11/02	Neovacs S.A. announced that it has received ?0.25 million in funding from Hanover Square Investments Pte Limted	CI

Market Cap	4.09K 4.77K 3.83K 3.5K 6.57K 457K 6.66K 45.2K 17.63K 229K 17.92K 17.53K 759K	P/E 2023 *	-	P/E 2024	-
Enterprise Value	-201K -235K -188K -172K -323K -22.45M -327K -2.22M -866K -11.28M -881K -862K -37.3M	EV / Sales 2023	-	EV / Sales 2024	-
Free-Float	99%	Yield 2023 *	-	Yield 2024	-

30/06	Neovacs bolsters its strategic intellectual property portfolio
11/02	Neovacs S.A. announced that it has received ?0.25 million in funding from Hanover Square Investments Pte Limted	CI
21/11	Neovacs S.A. Reports Earnings Results for the Half Year Ended June 30, 2025	CI
21/10/25	Neovacs S.A. announced that it expects to receive ?0.25 million in funding	CI
12/08/25	Neovacs S.A. announced that it has received ?0.25 million in funding from European High Growth Opportunities Manco S.A.	CI
30/04/25	Neovacs S.A. Auditor Raises 'Going Concern' Doubt	CI
30/04/25	Neovacs S.A. Reports Earnings Results for the Full Year Ended December 31, 2024	CI
17/03/25	Neovacs S.A. announced a financing transaction	CI
04/02/25	Neovacs: consideration of delisting, share price surges
04/11/24	Neovacs S.A. Reports Earnings Results for the Half Year Ended June 30, 2024	CI
02/11/24	Tech's Tangled Path with Microsoft
17/06/24	Neovacs: collaboration agreement with CNRS
10/06/24	Neovacs: presents results from vaccine candidates

1 day	+0.07%
1 week	-10.21%
Current month	-16.11%
1 month	-17.47%
3 months	-69.38%
6 months	-96.60%
Current year	-99.30%

NEOVACS Stock

Stocks

ALNEV

FR0014018EV4

Biotechnology & Medical Research

Valuation: NEOVACS

Chart: NEOVACS

Latest news : NEOVACS

News in other languages: NEOVACS

Quotes and Performance

Course Extremes

Managers and Directors: NEOVACS

Latest insider transactions

Other Biotechnology & Medical Research

Financials

Company Profile

Quotes

1 week	0.61	0.89
1 month	0.61	1.43
Current year	0.61	267
1 year	0.61	7,900
3 years	0.61	32,000,000
5 years	0.61	351,920,000
10 years	0.61	351,920,000

Date	Insider	Type	Main position	Quantity	% Market Cap.
27/2/21	Hugo Brugière	Sell	Chief Executive Officer	2,505,144	1.3796%
23/2/21	Hugo Brugière	Sell	Chief Executive Officer	6,391,053	3.5196%
23/2/21	Hugo Brugière	Sell	Chief Executive Officer	1,108,947	0.6107%

	2023	2024
Net sales	533K 623K 499K 457K 857K 59.58M 869K 5.9M 2.3M 29.93M 2.34M 2.29M 99M	434K 507K 406K 372K 698K 48.47M 707K 4.8M 1.87M 24.35M 1.9M 1.86M 80.53M
Net income	-8.74M -10.21M -8.18M -7.49M -14.05M -977M -14.24M -96.66M -37.69M -491M -38.33M -37.49M -1.62B	-32.91M -38.42M -30.8M -28.19M -52.91M -3.68B -53.61M -364M -142M -1.85B -144M -141M -6.11B
Net Debt	-237K -276K -221K -203K -380K -26.42M -385K -2.61M -1.02M -13.27M -1.04M -1.01M -43.89M	-205K -239K -192K -176K -330K -22.91M -334K -2.27M -884K -11.51M -899K -879K -38.06M